Metabolomics biomarkers in schizophrenia: An Overview

Metabolomics has emerged as a powerful tool for investigating the complex biological underpinnings of schizophrenia, offering insights into disease mechanisms and potential biomarkers. Through comprehensive analysis of small molecules in biological samples, metabolomics studies have revealed perturbations in various metabolic pathways in individuals with schizophrenia, highlighting the potential for improved diagnosis, prognosis, and treatment management. However, challenges such as validation, standardization, and integration with other omics data need to be addressed for the full realization of metabolomics' clinical potential in schizophrenia research and practice. This review examines the role of metabolomics in identifying biomarkers for early diagnosis of schizophrenia, emphasizing the importance of timely interventions for improved clinical outcomes. Metabolomics analyses have identified potential biomarkers, including altered levels of choline, ethanolamine plasminogen's, cytokines, and gene expression profiles, offering promise for early detection and personalized treatment strategies. Furthermore, lipidomic studies have elucidated differential effects of antipsychotic medications on lipid metabolism, underscoring the importance of personalized medication selection based on metabolic profiles. Emerging untargeted metabolomics approaches, such as data-independent acquisition strategies, provide comprehensive insights into metabolic alterations associated with schizophrenia onset and treatment response. Future directions include validation studies across diverse populations, standardization of protocols, integration with other omics data, and ethical considerations for responsible implementation in clinical practice. Collaborative efforts between researchers, clinicians, industry stakeholders, and regulatory bodies are essential to accelerate the clinical translation of metabolomics and improve outcomes for individuals affected by schizophrenia.